Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients (BRIDION)
Morbidly Obese Patients

About this trial
This is an interventional treatment trial for Morbidly Obese Patients
Eligibility Criteria
Inclusion criteria :
- ASA I-II-III
- Age 18 - 65 year
- Male or female
- BMI > 30
Exclusion criteria :
- Renal failure
- Liver dysfunction
- Breastfeeding female patients, or female patients without reliable contraception
- Neuromuscular disease
- Malignant hyperthermia or a family history of malignant hyperthermia
- Allergy for neuromuscular blocking agents or other medications used during general anesthesia
- Infectious disease or patients with fever
- Patients who already received rocuronium or sugammadex on the day of the study
Sites / Locations
- Ghent University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
BMI < 50, Total Body Weight (TBW), 2mg/kg
BMI < 50, TBW, 4 mg/kg
BMI < 50, Ideal Body Weight (IBW), 2 mg/kg
BMI < 50, IBW, 4 mg/kg
BMI > 50, TBW, 2mg/kg
BMI > 50, TBW, 4mg/kg
BMI >50, IBW, 2 mg/kg
BMI >50, IBW, 4 mg/kg
Patients with a BMI < 50, who will be dosed according to total body weight.
Patients with a BMI < 50, who will be dosed according to total body weight.
Patients with a BMI < 50, who will be dosed according to ideal body weight.
Patients with a BMI < 50, who will be dosed according to ideal body weight.
Patients with a BMI > 50, who will be dosed according to total body weight.
Patients with a BMI > 50, who will be dosed according to total body weight.
Patients with a BMI > 50, who will be dosed according to ideal body weight.
Patients with a BMI > 50, who will be dosed according to ideal body weight.